GridAI Technologies Corp.
GRDX Healthcare Biotechnology
GridAI Technologies Corp.’s revenue for fiscal 2025 (year ended December 2025) was $36,300.00. In the quarter to June 2026, EPS fell 219.0%, free cash flow fell 2,641.0% and total debt fell 64.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow GRDX
GridAI Technologies Corp. (GRDX) P/E ratio
GridAI Technologies Corp. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.3× (June 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ALGS Aligos Therapeutics, Inc. compare | n/m |
| GRDX GridAI Technologies Corp. | n/m |
| NXTC NextCure, Inc. compare | n/m |
| MGX Metagenomi Therapeutics, Inc. compare | n/m |
| RNAZ TransCode Therapeutics Inc. compare | n/m |
| CVM Cel-Sci Corporation compare | n/m |
| BCTX BRIACELL THERAP compare | 1.5× |
| ATNM Actinium Pharmaceuticals, Inc. compare | 3.1× |
| GNTA Genenta Science S.p.A. Unsponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)